<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028725</url>
  </required_header>
  <id_info>
    <org_study_id>21457</org_study_id>
    <secondary_id>5UH3CA211457-04</secondary_id>
    <secondary_id>NCI-2021-08885</secondary_id>
    <nct_id>NCT05028725</nct_id>
  </id_info>
  <brief_title>Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Investigation of a Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muhimbili University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CapNostics, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current protocol, we propose a study to evaluate a novel, combined esophageal&#xD;
      sponge-methylation biomarker strategy for the early detection of esophageal squamous cell&#xD;
      carcinoma (ESCC) as well as its precursor, esophageal squamous dysplasia (ESD). This strategy&#xD;
      leverages the 'EsophaCap', a swallowable, retrievable sponge, with subsequent evaluation of&#xD;
      the sample using a novel molecular biomarker assay. This biomarker assay evaluates&#xD;
      methylation levels in three genes, which have been shown to differ significantly between ESCC&#xD;
      cases and controls in pilot studies. Detection of methylation markers highly associated with&#xD;
      ESCC could help identify patients with concurrent ESCC or at high risk of imminently&#xD;
      developing this condition. If successful, this strategy could result in a paradigm shift for&#xD;
      esophageal cancer control strategies in Tanzania and other high-incidence ESCC regions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the sensitivity and specificity of a diagnostic strategy combining esophageal&#xD;
      sponge sampling with the 'EsophaCap' sponge device with the EsoCAN assay, a novel molecular&#xD;
      biomarker assay, among patients with histologically-confirmed ESCC and controls.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the sensitivity and specificity of a diagnostic strategy combining esophageal&#xD;
      sponge sampling with the 'EsophaCap' sponge device with the EsoCAN assay, among patients with&#xD;
      histologically-confirmed ESD and controls.&#xD;
&#xD;
      II. To evaluate the safety and feasibility of 'EsophaCap' a swallowable and retrievable&#xD;
      sponge, as a non-invasive strategy for screening and early detection of ESCC and its&#xD;
      precursor, ESD, in Tanzania.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the sensitivity and specificity of a diagnostic strategy combining esophageal&#xD;
      sponge sampling using the 'EsophaCap' with standard cytology, among patients with&#xD;
      histologically-confirmed ESCC and controls.&#xD;
&#xD;
      II. To evaluate the sensitivity and specificity of a diagnostic strategy combining esophageal&#xD;
      sponge sampling using the 'EsophaCap' with standard cytology, among patients with&#xD;
      histologically-confirmed ESD and controls.&#xD;
&#xD;
      Participants will be on study for up to 38 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of True-Positives (sensitivity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESCC cases &amp; controls only)</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>The proportion of participants with a positive EsoCAN assay result, among patients with histologically-confirmed Esophageal Squamous Cell Carcinoma (ESCC). The following equation will be used as a cut point for ESCC using the EsoCAN assay [0.139*log2(gene A)] + [0.176* log2(gene B)] + [0.185* log2(gene C)], whereas a cutoff value (for the numerical index produced by this formula) of greater than -2.327 is classified as positive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of True-Negatives (specificity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESCC cases &amp; controls only)</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>The proportion of participants with a negative EsoCAN assay result for will be reported, among study participants who are classified as controls. The following equation will be used as a cut point for ESCC using the EsoCAN assay [0.139*log2(gene A)] + [0.176* log2(gene B)] + [0.185* log2(gene C)], whereas a cutoff value (for the numerical index produced by this formula) of less than -2.327 is classified as negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of True-Positives (sensitivity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESD cases &amp; controls only)</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>The proportion of participants with both a positive EsoCAN assay result, among patients with histologically-confirmed Esophageal Squamous Dysplasia (ESD). The following equation will be used as a cut point for ESD: [0.139*log2(gene A)] + [0.176* log2(gene B)] + [0.185* log2(gene C)], whereas a cutoff value (for the numerical index produced by this formula) of greater than -2.327 is classified as positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of True-Negatives (specificity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESD cases &amp; controls only)</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>The proportion of participants with a negative EsoCAN assay result will be reported. The following equation will be used as a cut point for ESD: [0.139*log2(gene A)] + [0.176* log2(gene B)] + [0.185* log2(gene C)], whereas a cutoff value (for the numerical index produced by this formula) of less than -2.327 is classified as negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of study participants who successfully swallow the esophageal sponge device</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>The success of swallowing the esophageal sponge device will be determined by the clinical team overseeing the EsophaCap' administration and categorized as a dichotomous response of Yes (successful) or No (not successful).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of study participants who experienced an esophageal sponge device-related adverse event</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>Adverse events reported by the participants will be graded and classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and reported by group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Acceptability Scores</measure>
    <time_frame>Up to 38 days</time_frame>
    <description>Participants will be asked to rate their satisfaction with their experience with the EsophaCap sponge procedure after the procedure is complete by selecting a score on a scale with corresponding facial images with scores ranging between 0='Best Experience' (large smile on facial expression) to 10='Worst experience' (crying and frowning facial expression).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">289</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Esophageal Squamous Dysplasia</condition>
  <arm_group>
    <arm_group_label>Esophageal Squamous Cell Carcinoma (ESCC) Cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each study participant will undergo esophageal sponge sampling using the 'EsophaCap' sponge device. Group 1 will include a safety-phase, which will consist of a lead-in cohort of 8 patients with ESCC. Subsequent recruitment of ESCC Cases (Group 1) will not commence until the Data Safety Monitoring Board (DSMB) has deemed the safety lead-in data appropriate for continuation. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ESCC, Esophageal squamous dysplasia (ESD) Cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ESCC, Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EsophaCap Sponge</intervention_name>
    <description>Non-invasive strategy to sample esophageal tissue</description>
    <arm_group_label>Esophageal Squamous Cell Carcinoma (ESCC) Cases</arm_group_label>
    <arm_group_label>Non-ESCC, Control Group</arm_group_label>
    <arm_group_label>Non-ESCC, Esophageal squamous dysplasia (ESD) Cases</arm_group_label>
    <other_name>EsophaCap Sponge Device</other_name>
    <other_name>EsophaCap Swallowable Sponge device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chromoendoscopy</intervention_name>
    <description>Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus</description>
    <arm_group_label>Non-ESCC, Control Group</arm_group_label>
    <arm_group_label>Non-ESCC, Esophageal squamous dysplasia (ESD) Cases</arm_group_label>
    <other_name>Lugol's iodine chromoendoscopy</other_name>
    <other_name>Chromoendoscopic screening</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EsoCAN assay</intervention_name>
    <description>Biomarker Test</description>
    <arm_group_label>Esophageal Squamous Cell Carcinoma (ESCC) Cases</arm_group_label>
    <arm_group_label>Non-ESCC, Control Group</arm_group_label>
    <arm_group_label>Non-ESCC, Esophageal squamous dysplasia (ESD) Cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ESCC Cases:&#xD;
&#xD;
          -  Male or female &gt;= 18 years of age at screening visit.&#xD;
&#xD;
          -  Patients are currently seen for clinical care at Muhimbili National Hospital&#xD;
             (MNH)-Upanga or at MNH-Mloganzila.&#xD;
&#xD;
          -  Patients with a diagnosis of ESCC as evidenced by histological confirmation.&#xD;
&#xD;
          -  Patient must be able to swallow liquid (Ogilvie's score &lt; 3).&#xD;
&#xD;
          -  Patients must be well enough to participate in a 20-minute interview or have a close&#xD;
             relative who is able to do so on their behalf.&#xD;
&#xD;
          -  Patients must be willing to be contacted either in person or via phone 7-10 days&#xD;
             following administration of the 'EsophaCap' sponge device.&#xD;
&#xD;
          -  Native of Tanzania.&#xD;
&#xD;
          -  Written informed consent (and assent when applicable) obtained from subject or&#xD;
             subject's legal representative and ability for subject to comply with the requirements&#xD;
             of the study.&#xD;
&#xD;
        Non-ESCC study participants:&#xD;
&#xD;
          -  Male or female â‰¥ 18 years of age at screening visit.&#xD;
&#xD;
          -  Patients are currently seen for clinical care at MNH-Upanga or at MNH-Mloganzila.&#xD;
&#xD;
          -  Patient is scheduled to undergo EGD for a suspected non-malignant condition with no&#xD;
             symptoms concerning for esophageal cancer (i.e. dysphagia or odynophagia)&#xD;
&#xD;
          -  Patient must be able to swallow liquid (Ogilvie's score &lt; 3).&#xD;
&#xD;
          -  Patients must be well enough to participate in a 20-minute interview or have a close&#xD;
             relative who is able to do so on their behalf.&#xD;
&#xD;
          -  Patients must be willing to be contacted either in person or via phone 7-10 days&#xD;
             following administration of the 'EsophaCap' sponge device.&#xD;
&#xD;
          -  Native of Tanzania.&#xD;
&#xD;
          -  Written informed consent (and assent when applicable) obtained from participant or&#xD;
             participant's legal representative and ability for subject to comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        ESCC Cases:&#xD;
&#xD;
          -  Known pregnancy during participation in the study.&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          -  Clinical instability (i.e. hypotension or a recent cardiovascular event).&#xD;
&#xD;
          -  Any history of upper gastrointestinal bleeding within the past 3 months (including&#xD;
             reported history of hematemesis and/or melena).&#xD;
&#xD;
          -  Diagnosis of peptic ulcer disease within the last 3 months.&#xD;
&#xD;
          -  Known history of esophageal varices.&#xD;
&#xD;
          -  Patients taking anticoagulation or antiplatelet therapy/medication (warfarin,&#xD;
             clopidogrel, aspirin, heparin or enoxaparin) for high-risk conditions.&#xD;
&#xD;
          -  Patients with an active extra-esophageal malignancy (not currently in remission).&#xD;
&#xD;
          -  Patient with a known history of a non-malignant esophageal stricture.&#xD;
&#xD;
          -  Patients with esophageal stents currently in place.&#xD;
&#xD;
          -  Patients with a history of radiation therapy to the head, neck, any part of the&#xD;
             gastrointestinal tract (including esophagus) or thorax.&#xD;
&#xD;
          -  Patients who have previously received chemotherapy in the last 12 months&#xD;
&#xD;
          -  Patients with any history of major surgery for esophageal cancer (e.g. esophageal&#xD;
             bypass, esophagectomy, etc.).&#xD;
&#xD;
          -  Patients who have a known history of or clinical symptoms concerning for&#xD;
             tracheoesophageal fistula (aspiration history, severe cough)&#xD;
&#xD;
          -  Patients with a known history of small bowel obstruction&#xD;
&#xD;
          -  Patients with a history of bleeding complications during esophageal biopsy performed&#xD;
             for histological confirmation.&#xD;
&#xD;
          -  Patients with any history of a head and neck malignancy.&#xD;
&#xD;
          -  Patients with a known bleeding disorder&#xD;
&#xD;
          -  Patients with known thrombocytopenia (less than 50,000 platelets per microliter)&#xD;
&#xD;
          -  Individuals who are not permanent residents or natives of Tanzania.&#xD;
&#xD;
          -  Inability to follow instructions.&#xD;
&#xD;
          -  Unable to provide informed consent.&#xD;
&#xD;
        Non-ESCC study participants:&#xD;
&#xD;
          -  Known pregnancy during participation in the study.&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          -  Clinical instability (i.e. hypotension or a recent cardiovascular event).&#xD;
&#xD;
          -  Any history of upper gastrointestinal bleeding within the past 3 months (including&#xD;
             reported history of hematemesis and/or melena).&#xD;
&#xD;
          -  Diagnosis of peptic ulcer disease within the last 3 months.&#xD;
&#xD;
          -  Known history of esophageal varices.&#xD;
&#xD;
          -  Patients taking anticoagulation or antiplatelet therapy/medication (warfarin,&#xD;
             clopidogrel, aspirin, heparin or enoxaparin) for high-risk conditions.&#xD;
&#xD;
          -  Patients with an active extra-esophageal malignancy (not currently in remission) or&#xD;
             any history of a non-cutaneous malignancy diagnosed within the previous five years.&#xD;
&#xD;
          -  Patient with a known history of esophageal strictures disabling passage of the&#xD;
             capsule.&#xD;
&#xD;
          -  Patient with esophageal stents currently in place.&#xD;
&#xD;
          -  Patients with a history of radiation therapy to the head, neck, any part of the&#xD;
             gastrointestinal tract (including esophagus) or thorax.&#xD;
&#xD;
          -  Patients with a known history of small bowel obstruction&#xD;
&#xD;
          -  Patients with a known bleeding disorder&#xD;
&#xD;
          -  Patients with known thrombocytopenia (less than 50,000 platelets per microliter)&#xD;
&#xD;
          -  Individuals who are not permanent residents or natives of Tanzania.&#xD;
&#xD;
          -  Allergy to iodine&#xD;
&#xD;
          -  Presence of goiter.&#xD;
&#xD;
          -  Inability to follow instructions.&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Steitz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffrey Buckle, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geoffrey Buckle, MD, MPH</last_name>
    <phone>508-380-9129</phone>
    <email>geoffrey.buckle@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Muhimbili National Hospital (MNH)</name>
      <address>
        <city>Dar Es Salaam</city>
        <state>Mloganzila</state>
        <country>Tanzania</country>
      </address>
    </facility>
    <contact>
      <last_name>Yona Ringo</last_name>
      <phone>+255 756 680 746</phone>
      <email>yona.skills@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Muhimbili National Hospital (MNH)</name>
      <address>
        <city>Dar Es Salaam</city>
        <state>Upganda</state>
        <country>Tanzania</country>
      </address>
    </facility>
    <contact>
      <last_name>Yona Ringo</last_name>
      <phone>+255 756 680 746</phone>
      <email>yona.skills@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EsophaCap</keyword>
  <keyword>EsophaCapTM</keyword>
  <keyword>Biomarker Detection</keyword>
  <keyword>Cancer Detection</keyword>
  <keyword>Chromoendoscopic screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lugol's solution</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

